Efficacy and safety of advanced hybrid closed loop systems in children with type 1 diabetes younger than 6 years.
Humans
Diabetes Mellitus, Type 1
/ drug therapy
Male
Child, Preschool
Female
Insulin Infusion Systems
Prospective Studies
Blood Glucose
/ analysis
Insulin
/ administration & dosage
Hypoglycemic Agents
/ therapeutic use
Infant
Glycemic Control
/ methods
Follow-Up Studies
Blood Glucose Self-Monitoring
/ methods
Treatment Outcome
Hypoglycemia
Glycated Hemoglobin
/ analysis
Child
AHCL
CSII (continuous subcutaneous insulin infusion)
T1D (type 1 diabetes)
children
insulin
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2024
2024
Historique:
received:
06
02
2024
accepted:
19
04
2024
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
5
6
2024
Statut:
epublish
Résumé
Tight glycemic control is essential for the normal growth and development of preschool children. The aim of our study was to evaluate the impact of advanced hybrid closed loop (AHCL) systems in a real-life setting in children younger than 6 years. We conducted a two-center prospective study. We enrolled 19 patients with a median age at disease onset of 2.6 years [interquartile range (IQR) 1.6; 4.4] and a median disease duration of 1.4 years (IQR 0.9; 2.8) who were switched to AHCL from multiple daily injections or open-loop insulin therapy and with a 6-month follow-up. Clinical data, sensor glycemic metrics, and pump settings were collected and analyzed. After 6 months of follow-up, there was a significant reduction in median HbA1c ( AHCL systems are effective and safe for children younger than 6 years and should be considered as a valid therapeutic option from diabetes onset.
Sections du résumé
Background
UNASSIGNED
Tight glycemic control is essential for the normal growth and development of preschool children. The aim of our study was to evaluate the impact of advanced hybrid closed loop (AHCL) systems in a real-life setting in children younger than 6 years.
Methods
UNASSIGNED
We conducted a two-center prospective study. We enrolled 19 patients with a median age at disease onset of 2.6 years [interquartile range (IQR) 1.6; 4.4] and a median disease duration of 1.4 years (IQR 0.9; 2.8) who were switched to AHCL from multiple daily injections or open-loop insulin therapy and with a 6-month follow-up. Clinical data, sensor glycemic metrics, and pump settings were collected and analyzed.
Results
UNASSIGNED
After 6 months of follow-up, there was a significant reduction in median HbA1c (
Conclusion
UNASSIGNED
AHCL systems are effective and safe for children younger than 6 years and should be considered as a valid therapeutic option from diabetes onset.
Identifiants
pubmed: 38836230
doi: 10.3389/fendo.2024.1382920
pmc: PMC11148265
doi:
Substances chimiques
Blood Glucose
0
Insulin
0
Hypoglycemic Agents
0
Glycated Hemoglobin
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1382920Informations de copyright
Copyright © 2024 Rapini, Martino, Arnaldi, Deodati, Anagnostopoulou, Amodeo, Ciampalini, Pampanini, Lorubbio, Tosini, Cianfarani and Schiaffini.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor MD declared a past co-authorship with the authors NR and RS.